Champignon Brands Inc (CSE:SHRM) (OTCBQ:SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, said it has appointed Pat McCutcheon to its board of directors effective immediately.
McCutcheon is currently the chief executive of MediPharm Labs Corp (TSX:LABS), a global cannabis company he initially founded after identifying an important, overlooked segment of the burgeoning cannabis market to create the first pure-play cannabis company focused solely on extraction and API manufacturing.
Champignon noted that McCutcheon was paramount in raising capital to finance MediPharm's vision, thus creating a top-five cannabis revenue-generating company within the Canadian cannabis industry in the span of three years. Prior to founding MediPharm, McCutcheon held senior roles at various large pharmaceutical companies including Jansen Pharmaceuticals (Johnson & Johnson), Sanofi and AstraZeneca, where he was directly responsible for launching a wide range of medical products.
Gareth Birdsall, director of Champignon, said in a statement: “We are tremendously pleased to have Pat join the Champignon Board. His extensive experience in commercial development across the pharmaceutical industry combined with direct experience operating and scaling highly profitable businesses further strengthens our board with expertise that will accelerate the expansion of our clinical footprint via the establishment of net new clinical entities, as well as industry partnerships for ketamine, psilocybin and MDMA.”
McCutcheon commented: “I am excited to join the Board of Directors of Champignon given its leadership position with the only licensed operating ketamine clinic and integrated research centre of its kind in Canada."
“I look forward to working with the board and the company’s management team to advance Champignon’s clinical development and expansion program in the US and Canada. I also look forward to assisting the Company with its plan to evaluate other assets and new partnerships that will expand its pipeline in the rapidly emerging ketamine and psilocybin for mental health industry that has demonstrated strong potential in a short period of time”, he added.
Champignon also reported that it has appointed Matthew Fish, as its president and secretary. In his private practice as a securities lawyer, the company said Fish had developed extensive experience with respect to public companies, capital markets, as well as mergers and acquisitions. The firm added that Fish’s skillset will assist in accelerating its North American new clinical entity roll-out.
Champignon is currently focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform, as well as pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.
Contact the author of this article at [email protected]